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Introduction
A workshop on erythema nodosum leprosum (ENL) took place at the Parklane Hotel, Cebu
City, Philippines from 18th–20th February 2012. It was organised by the American Leprosy
Missions, the Leonard Wood Memorial Center for Leprosy Research and the Leprosy Group
at the London School of Hygiene and Tropical Medicine (LSHTM).
The workshop brought together 28 scientists and clinicians from a variety of disciplines
and organisations. Thirteen countries in Asia, the Americas, Australasia, Africa and Europe
were represented. A list of participants and their affiliations is given in the Appendix to
this report.
Structure of the Report
Part 1 of the report comprises a summary of salient points noted during the presentation of
research findings and disease profiles in the endemic countries represented. Part 2 is made up
of the consensus statements of the two working groups. They attempted to reach consensus on
current understanding, identify gaps in knowledge and prioritise research needs for the future.
They addressed the following topics:
Group 1: Clinical issues
Group 2: Laboratory science and pathology issues
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Part 1 – Plenary Sessions’ Report
Professor Diana Lockwood, one of the conveners of the workshop welcomed the participants
and thanked the Leonard Wood Memorial Center for hosting it. She gave a brief overview of
the clinical course of ENL and highlighted the challenges it poses:
1. Every centre has a relatively small number of patients, but ENL is an important cause of
morbidity in leprosy.
2. Thalidomide is an effective drug, but is not available in all countries due to teratogenicity.
3. Previous treatment trials have been of poor quality and a more robust body of evidence is
needed on which to base management recommendations.
4. The immunopathology of ENL remains obscure.
The Cochrane Review ‘Interventions for erythema nodosum leprosum’showed that good
quality data are lacking and that to improve this multicentre studies would need to be
performed.1
Professor Lockwood outlined the aims of the workshop:
1. To critically review the published evidence on treatment of ENL
2. To identify research topics which could improve patient outcomes
3. To identify studies needed to improve the understanding of the pathogenesis of ENL
4. To highlight improvements in the design of future clinical trials of treatments for ENL
5. To develop an ENL research network
There were presentations on the clinical burden and the management of ENL by participants
from the different endemic countries.
BRAZIL
Dr Anna Sales from Fiocruz, Rio de Janeiro, Brazil stated that between 1998 and 2010, 462
multibacillary (MB) patients were treated with 12 doses of WHO standard multi-drug therapy
(MDT) and followed annually for up to 10 years. The Ridley-Jopling classification of these
462 patients was 99 with mid-borderline leprosy, 151 patients with BL leprosy and 212
patients with LL. 60% of the 462 developed ENL. ENL occurred before and up to 6 years
after starting MDT.
The Brazilian Ministry of Health guidelines recommend the use of thalidomide or
prednisolone. High dose clofazimine and pentoxifylline are also recommended.2 At Fiocruz
patients with ENL are usually treated with thalidomide. Prednisolone and pentoxifylline are
used for individuals with recurrent ENL for whom thalidomide is not appropriate.
Dr Sales also presented cases of ENL which illustrated the varied clinical presentations of
ENL at Fiocruz. This included patients with extensive necrotic skin lesions and unusual
presentations such as parotid gland involvement.
Dr Jaison Barreto reported that at the Instituto Lauro de Souza Lima between 2006 and
2010, 397 patients were treated for ENL. 57% of LL patients had ENL. Thalidomide is used
often to manage patients with ENL. Thalidomide has a rapid onset of action and is very
effective. Dr Barreto reported that the effect of clofazimine and pentoxifylline was
disappointing. Azathioprine seemed to be effective but is expensive. Dr Barreto showed some
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unusual cases of ENL mimicking Sweet’s syndrome and erythema multiforme and cases of
necrotizing ENL.
ETHIOPIA
Dr Shimelis Doni described the recent experience at the All Africa Leprosy, Tuberculosis and
Rehabilitation Training Centre (ALERT) in Addis Ababa, Ethiopia where there were 327
new leprosy patients diagnosed in 2011and 2000 patients attending for reaction management.
In the previous two months, 85 patients had attended with ENL. Thirteen were inpatients.
12% of patients had had ENL for more than 2 years and 68% of all individuals with ENL were
classified as severe. 24% of patients had been taking prednisolone for more than 2 years.
Thalidomide is not available in Ethiopia.
INDIA
Dr Vivek V. Pai described how the Bombay Leprosy Project (BLP) covers 23 health posts
and is a referral centre. 265 patients with ENL were seen at the BLP from 2005 to 2011.
Clinical data on 56 patients indicated that 39 patients had a BI of 3 þ and above. 35 patients
had multiple episodes of ENL. Patients are treated with clofazimine, prednisolone and
thalidomide, and sometimes all three drugs in combination. Different brands of thalidomide
are available and this competition has lead to a reduction in cost. Thalidomide has been used
for approximately 6 years. The starting dose of thalidomide is 300 mg daily in divided doses.
The dose is then tapered and the patient maintained on 50 mg daily. 35% of patients develop
further ENL after stopping thalidomide.
NEPAL
Dr Mahesh Shah from Anandaban Hospital in Nepal described the experience in that referral
centre. In 2011, 137 new cases of leprosy were diagnosed. There were more than 100
admissions for reactions. A retrospective review indicated that 114 of 174 (66%) ENL
patients had LL. 51·3% of patients had ENL prior to the diagnosis of leprosy but others
developed their first episode of ENL within 5 years of initiation of MDT. 50% of patients
were still receiving treatment with prednisolone and/or thalidomide for their first episode of
ENL 18 months after it was diagnosed. The retrospective data from Anandaban suggests that
subsequent episodes of ENL are of shorter average duration than first episodes. Thalidomide
is available but expensive and rarely used in females. An inpatient stay is required for patients
while they are taking thalidomide. Dr Shah had found that MTX had some steroid sparing
effect in severe chronic, prednisolone-dependent patients with ENL. He has also given
azathioprine to some patients with ENL.
THE PHILIPPINES
Dr Marivic Balagon presented the experience of ENL at the Leonard Wood Memorial Center
during the three year period 2009–2011. More than 26% of patients with BL and LL leprosy
developed ENL. Approximately 45% had a BI greater than or equal to 4. 87% of cases of
ENL presented at diagnosis or in the three years following the diagnosis of leprosy.
The majority of patients were treated with prednisolone, thalidomide being unavailable in the
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country. She also presented the recently published data comparing patients treated with 12
or 24 months of MB MDT.3 Two separate cohorts of individuals, recruited in the periods
1985–1992 and 1998–2004, were followed for relapse. The individuals treated with the
shorter course of MDT did not have an overall increased risk of developing ENL, but the
severity appeared to be increased; BI greater than or equal to 4 was a significant risk factor. A
placebo controlled trial of clofazimine prophylaxis after completion of 12 months MDT is
now underway.
Professor Warwick Britton presented a review of ENL mechanisms which is to be
published separately. This described the evolution of our understanding of the
pathophysiology of ENL over the past four decades. ENL has long been known to be a
distinct clinical entity, with a histopathological picture of neutrophil infiltration and small
vessel vasculitis, but the underlying immune mechanisms are obscure. He outlined four phases
in our more recent understanding of the pathophysiology of ENL.
Immune Complexes
ENL has features resembling a Type III hypersensitivity disorder due to immune complexes
(IC).4 IC are a combination of antibody, antigen and complement. There is a polyclonal
antibody response in borderline lepromatous (BL) leprosy and lepromatous leprosy (LL).5
Skin blisters from ENL lesions contain IC,6 but they can also be found in patients without
ENL. M. leprae activates the complement pathway. However IC are not consistently
identifiable in ENL and are not a complete explanation of ENL. In IC disease anti-B cell
strategies or anti-antibody strategies are useful. In hepatitis C cryoglobulinaemia (an example
of an infectious cause of IC disease) it is important to block B cells but also to remove antigen
by treating the infection.
Tumour Necrosis Factor (TNF)
TNF was shown to be a critical cytokine in mediating ENL.7,8 TNF is present in the serum
and in ENL lesions.8,9 C-reactive protein (CRP) is usually raised in ENL.10,11 M. leprae and
lipoarabinomannan stimulate TNF from monocytes.12 Mononuclear cells from ENL patients
spontaneously release TNF.13
Thalidomide can cause a rapid fall in plasma TNF7 and blocks its release from monocytes
although not all patients have increased levels of TNF.14 Thalidomide has other mechanisms
of action as exemplified by its effect on lymphocyte proliferation in myeloma.15,16 TNF is a
marker of the proinflammatory response in ENL but it is not clear what triggers the release of
TNF and interleukin-6. The inhibition of TNF is a therapeutic aim, but some anti-TNF
strategies significantly increase the risk of tuberculosis.17 Blocking effector molecules such
as NF-kB downstream of TNF may have a role.
T Lymphocyte Activation
T cell responses may be relevant in ENL although they are normally minimal or absent in BL
and LL leprosy.18 Modlin showed an increase in the number of CD4 T cells in ENL compared
with other LL cases.19 Prolonged interferon-g therapy induced ENL in LL patients.20 There
may be a place for T cell inhibition with agents such as cyclophosphamide, pulse
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methylprednisolone or methotrexate (MTX). However the evidence is not strong enough to
explain the pathophysiology of ENL completely.
Neutrophil Recruitment
Gene expression in ENL lesions has recently been reported.21 Neutrophil recruitment genes,
including E-selectin, are upregulated and their expression increased compared to LL lesions.
Studies have repeatedly demonstrated that a high bacterial index (BI) is a risk factor for
the development of ENL which strongly suggests that the process is antigen driven.22,23 Slit
skin smears (SSS) are important for predicting those at highest risk but where SSS are not
done, another simple measure of antigen load is needed, such as phenolic glycolipid-1in
blood or urine.
In conclusion, Professor Britton emphasised the fact that ENL is a clearly recognised
clinical entity, but that there seems to a marked heterogeneity in the underlying
immunopathology. Thalidomide is certainly very effective in mitigating the condition, but the
search for safe alternatives has not so far been successful.
Dr Gigi Ebenezer gave a presentation on the pathology of ENL. The classical
histopathological features in ENL lesions are infiltration of neutrophils within pre–existing
macrophagic granulomas of lepromatous lesions often associated with vasculitis,
panniculitis, and macrophages with fragmented bacilli. Histological evidence of endothelial
damage with necrotizing vascular changes and thrombus formation reflect the heterogeneous
clinical presentation of ENL lesions. The role of B cells in the pathogenesis of ENL is unclear
and new studies are needed on the role of B cells in ENL because of the lack of contemporary
data. Gene expression in ENL lesions provides evidence of a local inflammatory mechanism
linking IL-1b, E-selectin and neutrophil recruitment. This is an important pathway for tissue
injury and thalidomide inhibits this neutrophil recruitment.21 E-selectin is a transmembrane
protein involved in neutrophil binding to endothelium, an initial step in neutrophil
recruitment. Alpha-1-acid glycoprotein levels were high in patients with ENL compared to
those with LL. The level of this acute phase protein decreased to normal levels after treatment
of ENL with thalidomide.24 The authors suggested this may be a useful biomarker of ENL.
Dr Barreto discussed some preliminary work concerning angiogenesis in leprosy. There is
increased expression of CD31 and CD105 in the skin lesions of patients with ENL compared
to other LL patients. CD31 is a marker of endothelial cells and lymphatics and CD105 a
marker of proliferating endothelial cells.25 These data indicate that further studies of CD105
in ENL might be useful.
Professor Lockwood discussed the treatment of ENL in detail emphasising its recurrent
nature.
The WHO Operational Guidelines mention steroids and ‘other drugs’ in the management
of ENL.26 The ILEP guidelines refer to the use of prednisolone, clofazimine and thalidomide
but do not address the issue of how to manage patients with chronic, recurrent ENL.27 The
Cochrane Review identified only 13 trials with 445 participants, most conducted prior to the
introduction of MDT.1 The review highlighted the methodological problems in the studies
including the absence of scales, no intention-to-treat (ITT) analyses and poorly defined
endpoints. The authors concluded that thalidomide has a significant effect. A further
conclusion was that clofazimine is better than prednisolone but this is counter to clinical
experience.
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The outcome measure in most studies is acute symptom control. The studies on
clofazimine in ENL are very short with data recorded for only 4-6 weeks. The time to the next
clinical episode was not reported. There has been one further randomised study comparing
thalidomide and prednisolone treatments published since the publication of the Cochrane
Review.28 Although thalidomide is known to be neurotoxic no systematic data has been
collected on this complication in leprosy patients. There is a paucity of data concerning other
potential agents for treating ENL which need further assessment in systematic studies
Azathioprine has not been studied in a randomised controlled trial (RCT) but a case series of
nine patients from Brazil has been reported.29
Ciclosporin is being used in a pilot study in Ethiopia. There is a report of ciclosporin in
three individuals who were not responsive to thalidomide.30 The use of the TNF inhibitors
infliximab and etanercept has been reported in one patient each.31,32
The recurrent nature of ENL results in many patients being treated with high doses of
corticosteroids for prolonged periods which exposes them to significant adverse effects.
Thalidomide is not available in all countries and is not suitable for all patients with ENL.
Effective treatments need to be identified, for those patients with recurrent ENL or those with
contraindication, which can be used instead of prednisolone and thalidomide. Another useful
approach would be the ability to identify patients at risk of ENL which would allow selection
of those who might benefit from prophylaxis.
Dr Saba Lambert from ALERT and LSHTM discussed the use of ENL severity scales.
Assessing clinical signs and severity of ENL is necessary for diagnosis and treatment. A
validated scale would empower researchers with an instrument for comparing their patients’
outcomes. The lack of comparable data has hindered the development of internationally
accepted treatment protocols and guidelines. A validated scale would aid the comparison of
therapeutic agents.
The items that have been used to assess the severity of ENL in different scoring systems
include the number of skin lesions, the presence of ENL lesion ulceration, the degree of fever,
the presence of neuritis and other extra-cutaneous manifestations.3,27,33 – 35 A standard
approach is required in order to measure a complex multi-system disorder such as ENL.
Dr Lambert discussed the preliminary findings of using a severity scale with 21 items.
Tender skin nodules, bone tenderness and peripheral oedema were the most common features
of ENL and fever (.37·58C) occurred in just 50% of patients classified as having severe
ENL. Nerve tenderness and ENL associated nerve function impairment (NFI) was common in
these Ethiopian patients. She advocated the development of a reliable severity scale,
validated in different populations which might be composed of: symptoms and signs, the
patient’s assessment of their pain severity, the duration of ENL and the ENL treatment
required. Dr Lambert also indicated that a scale useful as a research tool may differ
significantly from one used in routine clinical practice.
Dr Peter Nicholls presented a secondary analysis of ENL in the INFIR Cohort which
enrolled 303 MB patients.36 In total 16 patients were diagnosed with ENL. Five were
diagnosed using clinical criteria and a further 11 following a skin biopsy. Interestingly, only
two of the individuals diagnosed clinically had the histological features of ENL in their skin
biopsies. This has implications for the confirmation of ENL using histology as the gold
standard. The factors that were predictive of a diagnosis of ENL were the presence of fever
and a positive slit skin smear. Individuals with ENL appeared to have only modest NFI as
assessed by voluntary muscle testing or sensory testing with monofilaments, but there was
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evidence of significant subclinical nerve involvement using sensory and motor nerve
conduction and warm detection threshold.
Dr Steve Walker gave a presentation concerning design issues for RCTs in ENL. The
context for this was an interpretation of the findings of the four RCTs performed in the MDT
era (Table 1).
The pilot study by Girdhar and colleagues compared 10 patients randomly allocated to
receive intravenous betamethasone or placebo and oral steroids.37 The authors concluded that
there was no increased benefit of intravenous steroids compared with oral. Villahermosa
compared two different thalidomide regimens in 22 Filippino patients and noted rapid
symptom resolution.38 However 95% of patients had recurrence within eight weeks of
stopping thalidomide and 68% experienced mild or moderate adverse effects due to the drug.
A double blind RCT comparing pentoxifylline and thalidomide in 44 Brazilian patients for 30
days also demonstrated rapid symptom resolution with thalidomide.39 However recurrence
was not reported and 25% experienced adverse effects by day 7. The only study to compare
thalidomide and prednisolone was performed in India and enrolled 60 patients.28 The
treatment allocation was not concealed from the participants or the observers and thalidomide
was given for a longer period than prednisolone. Thalidomide had a quicker onset of action
and there was a very low rate of ENL recurrence of 6% in the thalidomide treated group
during the one year follow up period. This contrasted with 25% of the prednisolone treated
group experiencing recurrence on reducing to a dose of 10 mg daily. Adverse effects
attributed to thalidomide occurred in more than 30% of individuals. The adverse effects of
thalidomide reported in these studies were; somnolence, constipation, nausea, headache,
vertigo, pruritus, tremors, inability to concentrate and rash.
There are many possible interventions that might be studied as pilot projects or in larger
RCTs. A chosen intervention should be likely to have some effect, be widely available,
affordable and acceptable to patients. Having selected a study intervention choosing a
suitable control is essential. Thalidomide is considered to be the gold standard and there
might be ethical issues in designing a study that did not include a thalidomide arm. However
thalidomide is not considered effective in ENL associated neuritis and these patients have
often been excluded from studies. It would be useful to know the proportion of patients who
receive thalidomide as a first line agent in the management of ENL.
Table 1. Randomised controlled treatment trials in MDT treated leprosy patients with ENL
Study Intervention Number Recurrence rate Adverse events Comments
Girdhar37 Intravenous
betamethasone versus
placebo and oral
steroids
10 Unclear No significant
differences reported
Authors reported
no benefit of
intravenous
therapy
Villahermosa38 Thalidomide 22 95% recurred
within 8 weeks
68% No females.
Neuritis excluded
Sales39 Thalidomide versus
pentoxifylline
44 Not reported 25% by day 7 6 females.
Neuritis excluded.
Kaur28 Thalidomide versus
prednisolone
60 Thalidomide 6%.
Prednisolone 25%
at a dose of 10 mg
Thalidomide .30%.
Prednisolone more
than thalidomide.
No blinding.
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The following points are important for improving the design of future RCTs:
1. There are no prospective studies documenting the frequency of the clinical features of
ENL. This should be addressed.
2. Study inclusion criteria and robust clinical definitions are required
3. Future treatment studies also require well defined outcome measures and these should
include some measure of ENL recurrence.
Part 2 – Consensus Statements of the Working Groups
Dr Indira Kahawita gave feedback from Discussion Group 1 on Clinical Issues. The group
identified the following research priorities:
1. Second line drugs – steroid sparing agents and alternatives to thalidomide. There is a
pressing need to identify affordable and effective treatments of ENL. This will improve
outcomes for patients who only have access to prednisolone or in whom thalidomide is
contraindicated.
2. Natural history. In order to assess treatments and determine prognosis for patients we need
to define more clearly the following:
a. The range of clinical lesions seen in ENL cases
b. The geographical variations in incidence and clinical picture
c. Changes in the clinical picture over time (recurrent and chronic cases)
3. Validate a severity scale in order to have a quantitative outcome measure for assessing
efficacy of trial interventions. The weighting of some items may be necessary.
4. Identify risk factors for the development of ENL which might facilitate the use of
prophylaxis
a. Clinical parameters that parallel BI
b. CRP as a predictor of ENL
c. The role of stress and other psychosocial issues
5. Identify current management practices for ENL. There is widespread variation in
availability of treatments and how they are employed.
6. Best outcome measures for RCTs include:
a. Relief of acute symptoms
b. Time to recurrence of ENL
c. Total prednisolone dose used
d. Reduction in a validated ENL severity score
e. Quality of life assessment
What are the requirements for becoming a collaborating centre?
A descriptive study of the clinical features of ENL could include many centres, but it was
felt best to limit the group to present participants, at least initially. Prospective studies,
whether descriptive studies or clinical trials, will need a minimum number of patients
diagnosed with ENL each year. Collaborating centres would formally agree to share data.
Feedback from Group 2 on Laboratory issues was given by Dr Deanna Hagge. The Group
identified three themes for ENL laboratory research
International workshop on erythema nodosum leprosum 403
1. Studies of ENL pathogenesis
2. Studies elucidating predictors of ENL
3. Studies to improve ENL monitoring
These studies would ideally lead to field feasible tests with clinical relevance such as simple
blood, serum or urine assays. Potential biomarkers that could be investigated include CRP,
angiogenesis markers (CD105, vascular endothelial growth factor), cytokines, chemokines
and blood metabolites such as vitamin D, fatty acids and lipid mediators.
Investigation of pathogen specific indicators would be useful. Is there an epitope-antibody
shift associated with ENL? This might be investigated using B cell and T cell assays. Is there
a threshold or quantity of systemically available antigen that could be measured and
associated with ENL? Immunohistological studies could focus on the cellular infiltrate in
ENL but also examine epidermal nerve fibres as a potential marker of thalidomide toxicity.
Other ideas for potential research were the role of re-infection or persistent exposure, ENL
phenotype and M. leprae genotype correlation studies, differential expression in relation to
MDT exposure and genome wide scanning for host markers.
ENLIST GROUP INITIAL RESEARCH EXERCISE
It was agreed to collect prospective data on the clinical features of ENL in patients at first
presentation or those experiencing a recurrence or an exacerbation of ENL. This will be done
during 2012 and 2013 using agreed definitions and standardised data collection forms. The
objectives of this exercise are to:
1. Describe the clinical features of ENL
2. Describe the natural history of ENL
3. Determine current management practices
4. Determine features of severity
The initial data will be presented by each centre at the International Leprosy Congress in 2013
with publication of the pooled data in a peer-reviewed journal in early 2014.
Conclusion
The long-term goal of the ENLIST group is to conduct clinical trials of alternative treatments
for ENL and thus provide evidence for the rational treatment of the condition. In the short-
term, there is a need for a clearer definition of the clinical picture and course of ENL;
correlation of the clinical findings with histopathological findings and other biomarkers; the
development of a severity scale which could be used to monitor patients enrolled in a clinical
trial; and the development of a network of centres able to recruit, investigate and follow-up
significant numbers of ENL patients, as part of a multi-centre study.
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